Patents by Inventor Luc Juliaan Corina Van Rompaey
Luc Juliaan Corina Van Rompaey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10206907Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: August 15, 2016Date of Patent: February 19, 2019Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Javier Blanc, Nolwenn Jouannigot, Alastair James Hodges, Koen Kurt Smits
-
Publication number: 20170035738Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: ApplicationFiled: August 15, 2016Publication date: February 9, 2017Inventors: Christel Jeanne Marie MENET, Luc Juliaan Corina VAN ROMPAEY, Stephen Robert FLETCHER, Javier BLANC, Nolwenn JOUANNIGOT, Alastair James HODGES, Koen Kurt SMITS
-
Publication number: 20160296529Abstract: The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound.Type: ApplicationFiled: March 14, 2016Publication date: October 13, 2016Inventors: Gerben Albert Eleutherius van't Klooster, Florence Sylvie Namour, Reginald Christophe Xavier Brys, Luc Juliaan Corina van Rompaey
-
Patent number: 9415037Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: October 6, 2014Date of Patent: August 16, 2016Assignee: GALAPAGOS NVInventors: Christel Jeanne Marie Menet, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Javier Blanc, Nolwenn Jouannigot, Alastair James Hodges, Koen Kurt Smits
-
Patent number: 9284311Abstract: The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound.Type: GrantFiled: June 10, 2013Date of Patent: March 15, 2016Assignee: GALAPAGOS NVInventors: Gerben Albert Eleutherius van 't Klooster, Florence Sylvie Namour, Réginald Christophe Xavier Brys, Luc Juliaan Corina van Rompaey
-
Publication number: 20150150856Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: ApplicationFiled: October 6, 2014Publication date: June 4, 2015Inventors: Christel Jeanne Marie MENET, Luc Juliaan Corina VAN ROMPAEY, Stephen Robert FLETCHER, Javier BLANC, Nolwenn JOUANNIGOT, Alastair James HODGES, Koen Kurt SMITS
-
Patent number: 8853240Abstract: [1,2,4]triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.g.Type: GrantFiled: July 24, 2009Date of Patent: October 7, 2014Assignee: Galapagos NVInventors: Christel Jeanne Marie Menet, Nolwenn Jouannigot, Javier Blanc, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Alastair James Hodges, Koen Kurt Smits
-
Publication number: 20130345209Abstract: The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound.Type: ApplicationFiled: June 10, 2013Publication date: December 26, 2013Inventors: Gerben Albert Eleutherius van 't Klooster, Florence Sylvie Namour, Réginald Christophe Xavier Brys, Luc Juliaan Corina van Rompaey
-
Patent number: 8338124Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts, including bone formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject.Type: GrantFiled: November 21, 2009Date of Patent: December 25, 2012Assignee: Galapagos N.V.Inventors: Luc Juliaan Corina Van Rompaey, Peter Herwig Maria Tomme, Robin John Brown
-
Patent number: 8318137Abstract: The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring a compound-polypeptide property related to the differentiation of said cells. The invention further relates to a bone formation enhancing pharmaceutical composition, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject. Furthermore, the invention relates to a method for the in vitro production of bone tissue.Type: GrantFiled: October 30, 2009Date of Patent: November 27, 2012Assignee: Galapagos N.V.Inventors: Luc Juliaan Corina Van Rompaey, Peter Herwig Maria Tomme, Robin John Brown
-
Publication number: 20110190260Abstract: [1,2,4]Triazolo[1,5-a]pyridine compounds are disclosed that have a formula represented by the formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g. complications after bypass surgery or chronic endotoxin states contributing to e.g. chronic cardiac failure), diseases involving impairment of cartilage turnover (e.Type: ApplicationFiled: July 24, 2009Publication date: August 4, 2011Inventors: Christel Jeanne Marie Menet, Nolwenn Jouannigot, Javier Blanc, Luc Juliaan Corina Van Rompaey, Stephen Robert Fletcher, Alastair James Hodges, Koen Kurt Smits
-
Publication number: 20100093833Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts, including bone formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject.Type: ApplicationFiled: November 21, 2009Publication date: April 15, 2010Applicant: GALAPAGOS NVInventors: Luc Juliaan Corina Van Rompaey, Peter Herwig Maria Tomme, Robin John Brown
-
Publication number: 20100087509Abstract: The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring a compound-polypeptide property related to the differentiation of said cells. The invention further relates to a bone formation enhancing pharmaceutical composition, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject. Furthermore, the invention relates to a method for the in vitro production of bone tissue.Type: ApplicationFiled: October 30, 2009Publication date: April 8, 2010Applicant: GALAPAGOS N.V.Inventors: Luc Juliaan Corina Van Rompaey, Peter Herwig Maria Tomme, Robin John Brown
-
Patent number: 7638288Abstract: The present invention relates to in vivo and in vitro methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts, including bone formation enhancing pharmaceutical compositions, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject.Type: GrantFiled: June 29, 2006Date of Patent: December 29, 2009Assignee: Galapagos N.V.Inventors: Luc Juliaan Corina Van Rompaey, Peter Herwig Maria Tomme, Robin John Brown
-
Patent number: 7615626Abstract: The present invention relates to methods, agents and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts. The invention thus provides a method, comprising contacting a compound with a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID No: 194-309; and measuring a compound-polypeptide property related to the differentiation of said cells. The invention further relates to a bone formation enhancing pharmaceutical composition, and the use thereof in treating and/or preventing a disease involving a systemic or local decrease in mean bone density in a subject. Furthermore, the invention relates to a method for the in vitro production of bone tissue.Type: GrantFiled: October 23, 2006Date of Patent: November 10, 2009Assignee: Galapagos N.V.Inventors: Luc Juliaan Corina Van Rompaey, Peter Herwig Maria Tomme, Robin John Brown